Document:

ex101.htm

Exhibit 10.1

 

 

No. SYLEO20150730-1

 

Liaoning Senyuan Leo New Energy Electric Vehicle Co., Ltd.

 

 

Incorporation and Management Agreement

 

 

A Joint Venture Company co-founded by

 

 

Fushun Jinyuan Technology Machinery Manufacturing Co., Ltd.

 

 

And

 

 

Leo Motors,Inc

 

 

 

 

July 31, 2015

 

 

  

  

  

 

 

Joint Venture Company Agreement

 

Party A: Fushun Jinyuan Technology Machinery Manufacturing Co., Ltd.(Hereafter referred to briefly as JYT)

 

Party B: LEO MOTORS, INC.(Hereafter referred to briefly as LEO)

 

 

Based on The Law of The People’s Republic of China On Chinese-Foreign Equity Joint Ventures, Regulations for The Implementation of The Law of The People’s Republic of China On Chinese-Foreign Equity Joint Ventures and other related laws and regulations, JYT and LEO agree to set up the Joint Venture Company in The People’s Republic of China with joint investment and conclude the Joint Venture Company Agreement (Hereafter referred to briefly as The Agreement) as below.

 

 

Chapter 1  Investors and The Joint Venture Company

 

Article 1 Investors

 

	
1.

	
JYT is set up subject to the laws of The People’s Republic of China with registered address at Maqianzhai Village, Qingyuan Town, Qingyuan County, Fushun City in Liaoning Province.

Legal Representative:

Si Guicheng        Title: Chairman

	
2.

	
LEO is set up subject to the laws of The United States with registered address at 3887 PACIFIC ST, LAS VEGAS, NEVADA.

Legal Representative:

Shi Chul Kang     Title: Co-CEO,  Jun Heng Park   Title: Co-CEO

 

Article 2 Name and Location of the Joint Venture Company

 

Chinese Name:辽宁森源力奥新能源电动车有限公司

 

English Name: Liaoning Senyuan Leo New Energy Electric Vehicle Co., Ltd.

 

Korean Name:요녕센위엔레오신에네지전기차유한공사

 

Location: Maqianzhai Village, Qingyuan Town, Qingyuan County, Fushun City, Liaoning Province, P.R. China

 

Article 3 Organization Type of the Joint Venture Company

 

The organization type of the Joint Venture Company is Limited Liability Company. The liability of each party to the Joint Venture Company shall be limited to the amount it subscribes to the registered capital of the Joint Venture Company. The parties share the profits, risks and losses according to their capital contribution in the proportion of registered capital of the Joint Venture Company.

 

 

  

  

  

 

Article 4 Legal Position of the Joint Venture Company

 

The Joint Venture Company is a Chinese juridical person registering in Administration of Industry and Commerce of Qingyuan County and is under jurisdiction and protection of laws and regulations of China. All its activities shall be subject to laws, regulations and related rules of the People’s Republic of China.

 

 

Chapter 2  Purpose and Management Scope of the Joint Venture Company

 

Article 5 Purpose and Target of the Joint Venture Company

 

As an enterprise specializing in manufacturing electric vehicles, the Joint Venture Company will produce and market internationally competitive products and creat satisfactory benefits for both customers and investors by introducing internationally advanced technologies and cash and self-development. By making its effort, the Joint Venture Company aims to become a listed company in the near future.

 

Article 6 Management Scope of the Joint Venture Company

 

The Joint Venture Company is engaged in manufacturing, R&D and marketing including but not limited to new energy bus series of 6-12 meters, new energy modified sanitation vehicle series, light-type electric vehicle  series and other products approved by Board of Directors(BOD).

 

 

Chapter 3  Total Investment and Registered Capital

 

Article 7 Total Investment

 

The total investment amount is ¥411,600,000.

 

Article 8 Registered Capital

 

	
  

	
1.

	
The registered capital amount is ¥411,600,000.

	
  

	
2.

	
JYT will subscribe and invest ¥209,916,000 covering 51% of the registered capital.

	
  

	
3.

	
LEO will subscribe and invest ¥201,684,000 covering 49% of the registered capital.

 

Article 9 Investment Method and Deadline

 

	
  

	
(I)

	
JYT’s Investment Method: fixed property and cash

	
  

	
1.

	
Fixed property Investment: land, R&D buliding, plants, material warehouses and residence (see apprisal reports for details). JYT appoint 2 apprisal firms and LEO appoints 1 apprisal firm to apprise the qty. and value of fixed assets invested by JYT, the final apprisal price shall be the average of apprisal prices given by above mentioned 3 apprisal firms. It will be automally recognized as  that both parties agree on the final apprisal price.

 

 

  

  

  

 

	
  

	
2.

	
Cash: ¥20,000,000

	
  

	
3.

	
Deadline: Cash investment shall be completed within 90 days after the establishment date of the Joint Venture Company, property right of the fixed property shall be transferred within 90 days after the establishment date of the Joint Venture Company.

	
  

	
(II)

	

LEO’s investment method:Cash

 

	
  

	
1.

	
Cash: ¥201,684,000

	
  

	
2.

	
Deadline: cash investment of ¥20,000,000 shall be completed within 90 days after establishment date of the Joint Venture Company, the balance is ¥181,684,000. LEO shall contribute the stated capital strictly according to Project Schedule and Financial Budget  Plan of the Joint Venture Company. The value of stock rights shall be re-determined since Jan. 1st of 2017 as per current assessed value of the Joint Venture Company. LEO shall complement the contribution of capital acc. to the current assessed value of the Joint Venture Company.

	
  

	
(III)

	

When necessary time limit is needed due to related regulations on overseas investment of Chinese government and the US government, the date of first investment could be extended to 1.2 times of legally necessary time limit on 90 days base. If the first investment cannot be made as agreed, LEO shall negotiate with JYT and a decision shall be made after negotiation.

	
  

	
(IV)

	

When investment can not all be completed either by JYT or LEO, stock rights shall be kept for both parties according to their capital contribution of the Joint Venture Company. If both parties do not complete their obligation of capital contribution before Dec. 31st of 2016, each party shall still enjoy corresponding stock rights and perform its property rights based on their actual contribution of capital. Since Jan. 1st of 2017, each party shall enjoy its Stockholder’s equity acc. to its actual contribution of capital.

 

Chapter 4 Transferring Shares

 

Article 10 Transferring Shares

 

	
  

	
1.

	
Both parties can transfer its share holdings of the Joint Venture Company between each other.

	
  

	
2.

	
Either party can transfer all or portion of its shares of the Joint Venture Company to a third party. The transferor must get permission from the other party, applying for approval of Examining and Approving Authority and going through changing registration procedures. When one party decides to transfer all or portion of its share, the other party shall have the priority of refusal under equal condition.

	
  

	
3.

	
Each party has the obligation to notify the other party of relevant transferring conditions in written when transferring all or portion of its share of the Joint Venture Company. Within 30 days after receiving the written notification, the other party should perform or give up on refusal right and notify the party in written. If the other party doesn’t reply in written on performing or giving up the refusal in written within 30 days after receiving the written notification of transferring conditions, it shall be considered as it grants the selling to the third party. Meanwhile, all documents needed for the transferring, including written consent, shall be provided by the party giving up on refusal right and the party should coordinate on transferring and  authorize its proxy board member to vote for the bill.

	
  

	
4.

	
When performing the priority of refusal, the transferring condition shall be the same with that provided to the third party. The conditions provided by either party to the third party shall not be more preferential than that provided to the other party. If the transferring violates the above-stated regulations, it shall be considered as invalid.

 

 

  

  

  

 

 

Chapter 5 Liabilities

 

Article 11 JYT’s Liabilities

 

	
  

	
1.

	
Investment shall be completed as agreed in the Agreement.

	
  

	
2.

	
Preparing all necessary documents and assisting in handling administrative permission procedures needed for establishment of the Joint Venture Company and electric vehicle manufacturing.

	
  

	
3.

	
Assisting the Joint Venture Company in handling procedures of favorable policies in tax revenue and tariff and government subsidy and grants according to Chinese laws and regulations.

	
  

	
4.

	
Assisting the Joint Venture Company in recruiting necessary workers, technicians and management for production.

	
  

	
5.

	
Assisting in applying work visa of staff from LEO.

	
  

	
6.

	
Other affairs consigned by the Joint Venture Company.

	
  

	
7.

	
Providing Production License of Vehicle to the Joint Venture Company by compensated use. Both parties shall sign agreement on using the license.

	
  

	
8.

	
Ensuring the Joint Venture Company to acquire the business license to manufacture electric vehicles.

	
  

	
9.

	
After relevant vehicles are listed on government announcement and entering mass production, sales volume of the first 3 years is above 20,000. The scope of sales includes but is not limit to new energy bus series of 6-12 meters, new energy modified sanitation vehicle series, light-type electric vehicle  series and other products approved by The Board of Directors.

	
  

	
10.

	
During the Joint Venture Company’s usage of LEO’s technology, 10% of gross profit on sales of the Joint Venture Company will be transferred to LEO as technology transferring fee in amortization method. The fee shall be calculated from the actual sales date of products using LEO’s technology and the payment period is 10 years. The payment will be settled every quarter and should be paid within 6 working days after each quarter. JYT and LEO will sign attached Technology Agreement and Technology Permission Agreement which come into effect together with the Agreement.

	
  

	
11.

	
Gross profit is sales deducting all cost (except taxes). Relevant tax fee caused by technology transferring fee should be on LEO’s account.

 

 

  

  

  

 

Article 12 LEO’s Liabilities

 

	
  

	
1.

	
Investment shall be completed as agreed in the Agreement.

	
  

	
2.

	
Assisting the Joint Venture Company in choosing and purchasing machinery equipment and materials overseas and other matters.

	
  

	
3.

	
Providing technicians needed for equipment installing, debugging and trial production, manufacturing and inspection and training on technicians and workers of the Joint Venture Company.

	
  

	
4.

	
Responsible for manufacturing qualified products steadily based on design capacity within specified time period.

	
  

	
5.

	
10% of gross profit on sales of the Joint Venture Company will be collected by JYT as licensing fee (Production License No. 210400000087811) with a payment period of 10 years. As per the same condition of the usage of production license, the usage period of the production license can be extened by 10 year each time till the operation time limit of the Joint Venture Company.  However, once the Joint Venture Company gets the above Production License, the fee will not be paid any more. JYT and LEO will sign attached agreements on usage of Business License, trade mark, trade name, technology, patents and qualifications and the stated agreements will come into effect together with the Agreement. Relevant tax fee caused by production liscening fee should be on JYT’s account.

	
  

	
6.

	
Other affairs consigned by the Joint Venture Company.

	
  

	
7.

	
When the Joint Venture Company uses LEO’s core technology to manufacture “Powertrain” of electric vehicle, LEO independently owns the proprietary of technology when the powertrain is delivered. The “Powertrain” means all accessories to assemble the electric vehicle, including driving motor, controlling system, BMS, etc. The Joint Venture Company shall has priority to use LEO’s technology base on the same condition of Quality, Cost, Technology and Function.

	
  

	
8.

	
LEO has monopoly rights to sell and market the products manufactured by the Joint Venture Company in areas except China in the first 3 years after mass production and shall be responsible for international marketing. Both parties shall negotiate after 3 years.

	
  

	
9.

	
The patents applied and registered by the Joint Venture Company shall be owned by the Joint Venture Company. LEO can apply and register patents in other countries except China.

	
  

	
10.

	
Providing all documents and data needed by the Joint Venture Company.

	
  

	
11.

	
Technologies provided by LEO shall be complying with China’s laws and regulations and industry standard, ranking at leading edge of industry technology level and necessary for both products manufactured and sold and relevant management system regulating the stated products. The technologies of products and relevant professional knowledge and proprietary technology provided by LEO  include but are not limit to technical documents used for production guidance such as technical drawings, manuals, documents and other data. Relevant technology and service permission documents are attached below.

 

 

  

  

  

 

Chapter 6 Shareholder meeting

 

 

Article 13 Organization of Shareholder meeting

 

Shareholder meeting consists of legal representatives or authorized representatives of both parties.

 

 

Article 14 Shareholder meeting’s Rights

 

Shareholder meeting is the Highest Authority Organization of the Joint Venture Company and shall discuss and make decisions on all important policies and strategies of the Joint Venture Company.

 

 

Article 15 Shareholder meeting’s Authority:

 

	
  

	
1.

	
Making decisions on management policies and investment planning of the Joint Venture Company.

 

	
  

	
2.

	
Electing and changing directors and supervisors.

 

	
  

	
3.

	
Deliberating and approving on reports from BOD and supervisors.

 

	
  

	
4.

	
Deliberating and approving on annual financial budget plan and final accounts plan of the Joint Venture Company.

 

	
  

	
5.

	
Deliberating and approving on Profit Distribution Plan and Recovery of Loss Plan of the Joint Venture Company.

 

	
  

	
6.

	
Making resolutions on increasing or declining registered capital of the Joint Venture Company.

 

	
  

	
7.

	
Making resolutions on issuing the Joint Venture Company’s bond.

 

	
  

	
8.

	
Making resolutions on matters including company combining and division, changing company form, dissolution, liquidation etc.

 

	
  

	
9.

	
Deliberating and approving on the Joint Venture Company’s Articles.

 

	
  

	
10.

	
Making resolutions on shareholders transferring shares to person outside shareholders.

 

	
  

	
11.

	
Other important matters of the Joint Venture Company.

 

 

Article 16 Shareholder meeting

 

	
  

	
1.

	
Except that the first shareholder meeting is called and held by JYT, the following shareholder meeting should be called by the BOD and held by the Chairman.

	
  

	
2.

	
Regular shareholder meeting should be opened once a year. Interim shareholder meeting can be opened only when it is requested by shareholders representing 1/3 or more of voting right or requested by no less than 1/3 of directors or supervisors when BOD makes resolution that interim shareholder meeting is needed. Chairman of the BOD should notify each board member at least 30 days before opening each meeting by sending written notification indicating subject, time, and location of the meeting. The notification term can only be canceled by all shareholders in written form. Shareholders can entrust other person other than his legal representative in written form to present and vote on behalf of him. If a shareholder doesn’t present at meeting without any reason, it would be recognized as that the shareholder give up its rights on the matter voted.

	
  

	
3.

	
Shareholder meeting can be opened only when shareholders representing more than 2/3 of voting right are present. The resolution of matter discussed should be made by shareholder meeting.

	
  

	
4.

	
Shareholders perform voting right subject to capital contribution. Matters listed in the stated Article 15 must be approved by shareholders representing more than 2/3 of voting right.

 

 

  

  

  

 

Chapter 7   Board of Directors

 

 

Article 17   Organization and Terms of Directors

 

Board of Directors (BOD) of the Joint Venture Company shall be composed of 8 board members, and “JYT” and “LEO” shall have rights to name 4 members each. The serving terms of board members are 4 years, and they can be re-elected. If board member shall be replaced during the serving term, the successor shall be appointed by each party and serves for the remaining serving terms of the left board member.

 

 

Article 18   Chairman and Vice president of the Board

 

1. BOD committee shall have one chairman and two vice presidents. LEO shall appoint the Chairman of the BOD. “JYT” and “LEO” have the right to appoint each vice president. Both chairman and vice presidents shall serve for 4 years.

 

2. The chairman is the legal representative of the Joint Venture Company. If the chairman cannot fulfil his obligation for some reason or he doesn’t fulfil his obligation, the Chairman shall authorize the vice president or another board member to represent “the Joint Venture Company”.

 

 

Article 19 Rights

 

BOD committee is the Executive Organization of the Joint Venture Company, and it shall determine all important matters in daily operation activities.

 

 

Article 20 Resolution of General Matters

 

Decisions on the following matters can be made if more than a half of the attending board members of the meeting agree, and meanwhile at least one or more of the each party’s appointed board members agree.

 

1. Matters including acquisition, purchasing and selling and providing guarantee of the assets of the Joint Venture Company with values exceeding one million Chinese Yuan (CNY 1,000.000)

 

 

  

  

  

 

2. Compilation of annual management plan and investment budget

 

3. Compilation of annual final accounts plan and financial statement

 

4. Decision on the accounting policy, fund managements, and financing method

 

5. Appointment and dismissing of senior management including CEO and Vice General Managers, and decision of their rewards

 

6. Other matters stipulated in this Joint Venture Company Agreement, the Articles, or the matters required by BOD for resolution

 

 

Article 21   BOD Meetings

 

1. Regular BOD meeting must be made at least once per quarter. Whenever, more than 1/3 of board members request, interim meeting shall be opened.

 

2. In principle, BOD meeting should be held in the location where the Joint Venture Company is addressed. However, if necessary, it could be held in other places where the chairman or vice president appoints under permission of the Chairman.

 

3. Company board meeting can be only opened when more than 2/3 of the board members are present, and the bill can be passed with the agreement of more than half of the attending board members. Each board member has 1 voting right.

 

4. BOD meeting is called and held by the chairman, yet if chairman cannot call and hold the meeting, he/she shall entrust the vice president to call and hold the BOD meeting.

 

5. Board member can entrust other person to attend the BOD meeting on behalf of him/her to vote by issuing Letter of Authorization.

 

 

Article 22   Opening BOD Meeting

 

1. Chairman of the BOD committee should notify each board member by e-mail at least 14 working days before opening each regular BOD meeting. Meeting notification should indicate the time, location, method, and schedule of the meeting etc. Notification date shall be regarded as the date when all board members received the notification.

 

2. An interim BOD meeting can be opened when more than 1/3 BOD members request to open. When an interim BOD meeting is requested, chairman should send a written notice about opening an interim company BOD meeting to all BOD members within 5 working days from the date one received the request of the interim BOD meeting.

 

 

  

  

  

 

  If chairman fails to send the written notice of the interim BOD meeting in time, the board member, who suggested opening the interim BOD meeting, may send the written notice about the meeting timely. The written notice of the interim BOD meeting shall indicates time, location, method, bill of the meeting etc. The interim BOD meeting should be held at the date, which is after the 14th working days from the notification date. The meeting date cannot exceed 20th working days from the notification date.

 

3. If all board members agree, calling procedure of regular or interim BOD meetings can be omitted.

 

4. Notification of the BOD meetings shall be sent through e-mail to each board member. BOD committee must call to each board member to notify the opening of the meeting after the e-mail notification. Notification receipt date shall be the date when board members reply to confirm the notification. Each board member shall reply mail to confirm his/her receipt of notification within 48 hours from he/she receives the notification. If board member fails to respond the reply 48 hours from he/she receives the notification, it shall be regarded as the notification has been sent and received legally. If a board member does not reply to confirm receipt of the notification on purpose, it shall be regarded as the notification has been sent and received legally. If a board member changes the e-mail address, he/she must notify the change to the chairman in written.

 

 

Article 23   Meeting Minutes

 

BOD meetings minutes shall be kept in English, Chinese and Korean, and such minutes shall be signed by all attending board members or all proxy presenting members endorsed by board members. Minutes shall be stored by the Joint Venture Company.  The board member or proxy has right of access to the minutes. If there is any conflict in the translation of the minutes among languages, English minutes will get the priority in translation (The meeting minutes come in effect only when at least 1 board member of each party sign it).

 

 

Article 24   Reward and Payment Method

 

Board members shall not be entitled to be paid in any form from the Joint Venture Company unless the board member is employed by the Joint Venture Company, or perform the function of Joint Venture Company. Yet, Joint Venture Company shall be only responsible for cost of transportation, accommodation for travel to attend the BOD meetings and other reasonable cost directly used for “the Joint Venture Company”.

 

 

Chapter 8   Supervision

 

 

Article 25   Supervision

 

The Joint Venture Company shall have 2 supervisors, and JYT and LEO shall appoint one supervisor each, and BOD meeting approves the appointments. The serving term of each supervisor is 3 years, and supervisors can be re-elected.

 

  

  

  

 

Article 26   Rights and Responsibilities of Supervisors

 

1. A supervisor shall have the right to audit managerial and financial activities of the Joint Venture Company along with the right to request, and review all related written data and documents related with chairman, executives, and employees of the Joint Venture Company.

 

2. A supervisor supervises the job activities of chairman, executives, and employees, and they can request the dismissal of those who violates the laws, rules and regulations of the company and the government and resolution of the BOD committee.

 

3. If the activity of BOD members, executives is adverse to the interests of the Joint Venture Company, a supervisor has rights to request the corrections, cease, or improvements of such activity.

 

4. A supervisor has rights to  suggest a bill to the BOD meetings.

 

5. Supervisors can undertake other duties granted by the law, company regulation of the Joint Venture Company, or the investors.

 

6. Supervisors have rights to attend the BOD meetings. They can make inquiries or suggestions to the resolution of BOD meeting. But supervisor does not have the voting rights.

 

 

Chapter 9   Business Management Organization

 

 

Article 27   Organization and Serving Terms

 

1. Business management organization of the Joint Venture Company has 1 CEO, 1 Deputy General Manager, 1 CFO and 1 Financial Department Manager.

 

2. CEO shall be recommended by “JYT”; Vice General Manager shall be recommended by LEO; CFO shall be recommended by LEO; above stated management should be appointed by the BOD committee. Financial Department Manager shall be recommended by JYT and appointed by CEO. Each party should ensure that its elective board members agree the appointments of CEO, Vice General Managers, CFO and Financial Department Manager.

 

3. Serving terms of CEO, Vice president and CFO shall be determined by the BOD committee. Serving terms of department managers and other staff shall be determined by CEO.

 

4. If CEO, Vice General Managers and CFO shall be accused of accepting bribe or has made a grievous fault in work, such person can be dismissed anytime through the BOD meeting’ s resolutions. New CEO, Deputy General Managers and CFO shall be recommended and appointed according to the Article 27, Clause 2.

 

Article 28   Rights and Responsibilities of CEO

 

1. CEO executes all issues and matters decided by the BOD committee. CEO represents Joint Venture Company to perform other duties under the right to be given by the BOD committee.

 

 

  

  

  

 

2. Rights of CEO

 

CEO manages overall work of the Joint Venture Company under directions of BOD.

 

 

Chapter 10   Labor Management

 

 

Article 29   Company’s Value

 

The Joint Venture Company shall set the labor policy based on the related labor laws and regulations of China.

 

 

Article 30   Employee Remunerations

 

Employee’s salary, allowance, welfare, insurance, subsidy, bonus and other fringe benefits and other matters are set on the labor contract that the Joint Venture Company is going to enter with each employee. Employee’s salary standard is executed as “Equal Pay for Equal Work”.

 

 

Article 31   Labor Union

 

1. Employees of the Joint Venture Company in China may organize a Labor Union and perform Labor Union activities based on the “Labor Union Law of People’s Republic of China”, other related law of China’s Labor Union, and regulations of the administrative laws. Labor Union of the Joint Venture Company represents the benefit of employees of the Joint Venture Company.

 

2. The Joint Venture Company must provide funds to the Labor Union of the Joint Venture Company based to meet the requests of the China’s public fund related law and allow the Labor Union to use the funds.

 

 

Chapter 11   Tax and Profit Distribution

 

 

Article 32   Tax Treatment

 

The Joint Venture Company pays tax according to the law and regulations of China; also it shares preferential policies in tax and tariff according to the Chinese laws.

 

 

Article 33   Legal Reserve and Other Funds

 

1. The Joint Venture Company is comply with the Article 76 of Regulations for the Implementation of The Law of The People’s Republic of China on Chinese-Foreign Equity Joint Ventures.

 

2. The Joint Venture Company can take a certain rate of every year’s profit after tax deduction for employee encouragement and welfare fund and company development fund. The rate shall be determined by BOD.

 

 

  

  

  

 

Article 34   Profit Sharing

 

1. Remaining profits from the ‘Joint Venture Company” after taking legal reserve and other funds from the profit after tax deduction, shall be shared to the investors according to each party’s equity rate.

 

2. Within 3 months after each fiscal year, the BOD committee of the Joint Venture Company shall approve the profit sharing plan, and such shared profits are paid to each investor within 10 working days from the designated date in the plan.

 

3. The Joint Venture Company cannot share the profits before it makes up of all the losses from the previous fiscal years. Unshared profit surplus from the previous year can be shared together with the profit of current year in the current year.

 

4. The Joint Venture Company guarantees to remit legally shared profit of LEO to the shareholders in USA and Korea where LEO is located. If there is a third party shareholder other than LEO, The Joint Venture Company guarantees to remit the legally shared profits of the third party to those countries unless the remittance is restricted by the laws of China.

 

5. Approval of remedy plan for losses of the Joint Venture Company: JYT and LEO should share the losses according to each party’s equity rate. If there is a third shareholder, the remedy plan should be decided by shareholder meeting.

 

 

Chapter 12   Finance and Accounting

 

 

Article 35   Accounting System

 

1. Based on the laws, regulations of China, the Joint Venture Company shall estimate its finance and accounting system as per its circumstance and report/record at local financial department and tax authority.

 

2. The fiscal year of the Joint Venture Company shall be calendar year from January 1 to December 31. First fiscal year of the Joint Venture Company starts on the established date and ends on December 31st of the same year. Last fiscal year of the Joint Venture Company starts on January 1st of the year lasts until the date when the Joint Venture Company ends and closes its businesses officially.

 

3. The Joint Venture Company should report Quarter Financial Report within 30 days after each quarter to JYT and LEO. Annual report must be submitted to JYT and LEO before the end of February of each year.

 

4. Accounting currency of the Joint Venture Company shall be Chinese Yuan. If foreign transactions take place, in the convenience of the record, foreign currency amount shall be converted into the amount of the accounting currency. Any increase or decrease of the balance in the foreign transaction account shall be converted to the accounting currency based on the promulgated exchange rate of the conversion date reported by the People’s Bank of China.

 

 

  

  

  

 

5. The Joint Venture Company should honestly and accurately keep record and preserve the accounting books according to the related laws and regulations of China.

 

 

Article 36   Accounting Audit

 

The Joint Venture Company shall employ an independent and dependable   accounting firm that is registered and operated in China, and the employment of the firm must be approved by the BOD committee. The employed accounting firm shall perform an audit on annual financial statement and half year financial statement of the Joint Venture Company and submit financial audit report to the BOD committee and CEO.

 

 

Chapter 13   Bank Account and Foreign Currency

 

 

Article 37   Bank Account

 

The Joint Venture Company shall open a Chinese Yuan currency account and foreign currency account in approved banks in China.

 

 

Article 38   Joint Venture Company’s Foreign Currency Demand

 

All foreign currency related matters of the Joint Venture Company shall be based on the “Foreign Currency Management Implementations of People’s Republic of China” and officially promulgated other foreign currency related regulations.

 

 

Article 39   Expenses and Settlement

 

Unless agreed or required by the agreements, the Joint Venture Company pays with Chinese Yuan in all payments made in China.

 

 

Chapter 14   Management of Deadlock

 

 

Article 40   Treatment of Deadlock

 

After one party request bill to BOD meeting about resolution of BOD meeting regulated in this Agreement, if the BOD meeting cannot be opened or the number of board members attending or voting cannot reach valid quantity, which leads to resolution still cannot be made over 30 working days from the initial submission date of the bill, meanwhile, the party does not withdraw or discard the bill, the case should be discussed and decided by BOD meeting.

 

 

Article 41   Final Negotiation

 

If either JYT or LEO has notified another party of the Deadlock situation according to above Article, representative of JYT and LEO shall perform a final negotiation to resolve Deadlock within 30 working days.

 

 

  

  

  

 

 

Article 42   Treatment

 

Although the final negotiation was performed according to above Article, if they failed to reach the resolution, it shall be treated as below:

 

1. If both JYT and LEO wishes to solely operate the Joint Venture Company, both parties fail to reach the resolution after negotiation as per article 41, both parties must select one common notary organization legally registered in China within 30 working days from the date they fail to reach the resolution and suggest a written form of expected purchase price of each other’s equity and notarize such documents via notary lawyer. In this case, the party that has suggested a higher expected purchase price can buys the partial or entire equity of the other party at the notarized expected purchase price. The other party must cooperate in the equity transferring process.

 

2. If only one party wishes to solely operate the Joint Venture Company, the other party must transfer the partial or entire equity to the other party. In this case, JYT and LEO both shall mutually delegate PWC, Deloitte, KPMG, or Ernst & Young operated in China or reputable asset appraisal organization to perform an evaluation on the pre-transferred equity, and the appraisal price shall be regarded as transferring price. The transferring party must fully cooperate in the necessary process for the equity transfer.

 

3. If both JYT and LEO do not wish to operate Joint Venture Company within 30 working days from the date when the negotiation based on the Article 41 failed, it shall be considered as JYT and LEO agree to dissolute the Joint Venture Company. In such case, it shall be processed according to the regulations set in Chapter 16 of the Agreement.

 

 

Chapter 15   Management Period

 

 

Article 43   Management Period

 

Management period of the Joint Venture Company is 50 years. If all parties unanimously decide to extend the management period and after resolution of BOD meeting, the Joint Venture Company can extend the management period with applying in written at the Examining and Approving Authority or committee empowered by the Examining and Approving Authority 6 months before the termination and handle registration changing procedures at Industry and Commercial Administrative Management Department.

 

 

Chapter 16   Dissolution and Liquidation

 

 

Article 44   Dissolution

 

The Joint Venture Company dissolves in the following cases:

 

1. If management period is terminated,

 

2. If the Joint Venture Company cannot continue its businesses because of critical losses,

 

 

  

  

  

 

3. Because one party violates this Agreement and/or company regulations, the Joint Venture Company cannot continue its businesses for such violation(s),

 

4. If the Joint Venture Company cannot continue its business due to significant damage from force majeure such as natural disaster and war etc.

 

5. If the Joint Venture Company does not attain its business purposes and goals, and if there is no improvement,

 

6. If other dissolution cause set in the Agreement and company regulations of Joint Venture Company occurs.

 

 

Article 45   Liquidation

 

1. If the Joint Venture Company announces dissolution, it shall be liquidated. The Joint Venture Company shall organize liquidation committee according to the Chinese Company Law and other related regulation. Liquidation committee shall be responsible for the liquidation process.

 

2. The Joint Venture Company shall handle debts with total asset. Surplus asset after repaying such debt shall be allocated to both JYT and LEO according to each party’s capital contribution rate.

 

3. After liquidation of the Joint Venture Company is completed, liquidation completion report prepared by the liquidation committee shall be submitted to BOD meeting, and such report shall pass the shareholder meeting. The Joint Venture Company shall report to the Examining and Approving Authority and then cancel its business registration to the registration management organization.

 

 

Chapter 17   Breach of an Agreement and Termination

 

 

Article 46   Breach of an Agreement

 

1. If the partial or entire Agreement cannot be executed due to a breach of an agreement by either JYT or LEO, the violating party shall be responsible for the breach. If both parties have breached the agreement, each party shall be responsible for the agreement breach based on the actual situation.

 

2. If the Agreement or its attachments cannot be implemented or fully implemented due to one party’s fault, the default party shall bear breaching obligation. If both parties have breached the agreement, each party shall be responsible for the agreement breach based on the actual situation.

 

 

Article 47   Termination

 

If either JYT or LEO violated the responsibilities set in item 3 of article 44 of chapter 16 of the Agreement, and does not amend such actions within 10 working days from the date that the agreement observing party requested amendment, the agreement observing party can terminate the Agreement and notify the termination of the Agreement to the violating party. In such case, the agreement observing party can ask for the compensation of loss or damages caused by the behavior of the violating party to the party that breached the Agreement.

 

 

  

  

  

 

When the Joint Venture Company comes to liquidation or termination, the Joint Venture Company shall return all technical data provided by each party separately. The technical data includes documents, project files, design drawings, videos, e-documents and so on. After liquidation or termination, LEO and JYT shall be responsible for the after sales service of vehicle on technical aspect. Illegal user shall compensate all damages to the other party and bears all legal responsibility brought by illegally using unreturned technical data.

 

 

Chapter 18   Confidentiality

 

 

Article 48   Confidentiality

 

1. Both parties shall not disclose any confidential business information of the Joint Venture Company or of the other party that was acquired in the process of executing this Agreement to other companies, organizations or individuals. But the confidential information can be disclosed if the information is requested by or from the laws, regulations, government or courts of China or USA, or if the confidential information owner agrees to disclose prior to the disclosure.

 

2. If the employee of one party violates the item 1 of this Article and this violation has caused losses or damages to investors, the violating party must compensate the losses or damages made.

 

3. Entire content of the Agreement is subject to the confidentiality clauses. But the content can be selectively used by parties and IR of the Joint Venture Company for their own development in foreign activities.

 

 

Chapter 19   Applicable Law and Resolution of Dispute

 

 

Article 49   Applicable Law

 

Signing the Agreement, its effect, interpretation, execution, amendment, termination and resolution of the dispute shall be abided by the laws of China.

 

 

Article 50 Resolution of Dispute

 

If any dispute shall arise between JYT and LEO regarding this Agreement, it should be resolved by a friendly negotiation. If negotiation fails, a lawsuit must be submitted to the arbitration committee. All parties agree to submit disputes to  Beijing Chaoyang District Arbitration Commission for arbitration in accordance with its existing rules in effect at the time of applying for arbitration. The arbitration of arbitration commission shall be final and effective for each party.

 

 

  

  

  

 

Chapter 20    Others

 

 

Article 51    Abandonment of Right

 

When JYT or LEO does not strongly assert a certain article of the Agreement to be executed timely, it does not mean that the JYT or LEO abandons the right to request such right. Also, one time abandonment of right does not count as an abandonment of the similar claiming right or abandonment of the claiming right of rights and interests safeguarding against the other party’s violating behaviors.

 

 

Article 52   Attachments

 

All attachments to this Agreement shall have same legal effect as this Agreement.

 

 

Article 53   Agreement Completeness

 

This Agreement is the written expression of both parties’ true intention. It represents and replaces all oral and written negotiation, understanding and declaration of intention made between both parties in the past.

 

 

Article 54   Independence

 

Even if any regulation or article of this Agreement shall become invalid, lose its effect or determined to be non-executable by government, judicial office, or arbitrary organization, it shall not affect other articles of this Agreement.

 

 

Article 55   Languages

 

This Agreement is written in English, Chinese and Korean; if any difference is found in the translations among English, Chinese and Korean, English shall be prioritized.

 

 

Article 56   Effective Date and its Amendment

 

This Agreement shall be effective after it is approved by Examining and Approving Authority. Any changes of the Agreement shall be also as per this procedure.

 

 

Attachments:

 

1. Business Plan

 

2. Appraisal report of investment in kind to be contributed by JYT to Liaoning Senyuan Leo New Energy Electric Vehicle Co., Ltd.

 

3. Articles of Incorporation

 

4. Copy of License, Production License

 

5. Technical support and service agreement

 

 

  

  

  

 

6. Trade mark, trade name, qualification and patent licensing agreement

 

7. Further agreement after this agreement shall be attached in this agreement, and the further agreement has the priority to this agreement.

 

 

Date of Agreement:  July 31, 2015

 

Signed by

 

/s/Si Guicheng

 

_________________________________________

 

Si Guicheng, Chairman, Fushun Jinyuan Technology Machinery Manufacturing Co., Ltd.

 

 

and

 

 

/s/ Shi Chul Kang

 

_________________________________________

 

Shi Chul Kang, Co-CEO, LEO MOTORS, INC.

 

 

/s/ Jun Heng Park

 

_________________________________________

 

Jun Heng Park, Co-CEO, LEO MOTORS, INC.EX-10.18

 Exhibit 10.18 

May 11, 2015 
 Jonathan Graham 

XXXXXXXXXXXX 
 XXXXXXXXXXXX 

Dear Jonathan: 
 On behalf of Amgen, I am pleased
to offer you the position of SVP General Counsel & Secretary, Level 10, reporting to Robert A. Bradway. This offer and the compensation listed are subject to your appointment by our Board of Directors (the Board) and the Compensation and
Management Development Committee (the Compensation Committee) providing final approval of the compensation listed in this letter. 
 Your salary will be
paid bi-weekly in the amount of $34,231.00, with 26 pay periods in one year. 
 Provided that you sign a “Sign-On/Retention
Bonus Agreement for New Hire Staff Members” in the form provided by Amgen, you will be eligible to earn a bonus of $2,000,000.00, less federal and state tax deductions and other applicable deductions and withholdings, subject to the
terms of that Agreement. Please review that Agreement for information regarding timing and other payment details. 
 You will be granted time-vested
restricted stock units (RSUs) valued at $8,600,000. The actual number of RSUs will be 
 determined by dividing $8,600,000 by the closing price of
Amgen common stock on the expected grant date of August 4, 
 2015, providing you are actively employed on that date. Upon each applicable vesting date,
you will receive a number of 
 shares of Amgen common stock equal to the number of restricted stock units that vest, less any shares that
are withheld to 
 satisfy applicable taxes. This grant will vest beginning with the first anniversary of the grant date through the fourth

 anniversary of the grant date at a rate of 25% each year, respectively, contingent upon your being actively employed by 

Amgen through each vesting date. 
 Restricted stock units will be
subject to the terms and conditions set forth in the applicable grant agreement. 
 In addition, beginning in 2016, you will be eligible to
receive additional grants as part of Amgen’s Long Term Incentive (LTI) program. Grants under the LTI program are discretionary as approved by the Compensation Committee. 

You will be eligible to participate in Amgen’s Global Management Incentive Plan (the “GMIP”) pursuant to the terms of the GMIP.
Your annual target incentive opportunity will be 80% of your base salary earnings during the plan year. Awards under the GMIP are discretionary. Your actual GMIP bonus may be more or less than this target amount, and may vary based on Company
performance, any other criteria selected by the Company, and management’s assessment of your individual performance and contribution. You must be actively employed through the last regularly scheduled Amgen business day of the plan year to be
eligible for that year’s GMIP bonus. For purposes of the 2015 GMIP bonus, payable in 2016, we will guarantee a minimum Company performance multiplier of 130%, applied against your 2015 eligible earnings. 

You are also eligible to participate in the Amgen Nonqualified Deferred Compensation Plan (the “DCP”) to voluntarily defer, on a
pre-tax basis, a portion of your annual earnings, including base salary, commissions, and/or GMIP bonus. Shortly after commencing your employment at Amgen, you will receive an enrollment e-mail regarding the DCP plan for Amgen. A Q&A regarding
the DCP is enclosed. 
 Amgen will credit $2,000,000.00 on your behalf to the Amgen Nonqualified Deferred Compensation Plan (the
“DCP”), a nonqualified and unfunded executive benefit plan that permits Amgen to credit contributions on behalf of staff members as a “Company Contribution Amount” (as defined in the DCP). Your $2,000,000.00 Company
Contribution Amount will vest as follows: 
 20% on the 1st anniversary of the date of your
employment with Amgen and its subsidiaries. 
 20% on the 2nd anniversary of the date of your
employment with Amgen and its subsidiaries. 
 20% on the 3rd anniversary of the date of your
employment with Amgen and its subsidiaries. 
 20% on the 4th anniversary of the date of your
employment with Amgen and its subsidiaries. 
 20% on the 5th anniversary of the date of your
employment with Amgen and its subsidiaries. 

  
 1 

 Upon vesting, each portion of the contribution plus any gains or losses are subject to FICA and
will be withheld as soon as possible from your next available payroll check. 
 This credit, plus any credited earnings (or minus any
losses) will be paid to you after your “Separation from Service” (as defined in the DCP) in accordance with the terms of the DCP. Generally, Separation from Service means the termination of your employment with Amgen and its subsidiaries.
Please note that Company contributions are not eligible for the Short-Term Payout provision of the DCP. 
 In addition, your position will
make you eligible to participate in the Amgen Inc. Change of Control Severance Plan, as amended from time to time (the “COC”). COC eligibility and benefit levels are determined immediately prior to a “Change of Control” as
defined in the COC. If, upon your termination, you are eligible to receive severance benefits under the COC and you are also eligible to receive severance benefits from another plan agreement or other source, you will be paid the greater of the
amount from that plan or the amount provided in the COC, but not both amounts. A copy of the COC is enclosed. 
 If, within the first 3
years of your employment with Amgen, Amgen terminates your employment without “Cause”, as defined below, you will be entitled to the benefits described in this paragraph (the “Termination Paragraph), provided that you sign a general
release in the form furnished to you by Amgen and do not timely revoke it. The following are such benefits: two (2) times the sum of your annual base salary, then in effect, and target cash incentive opportunity (i.e., GMIP or successor bonus
plan target, which is currently 80%), then in effect, paid in a lump sum as soon as administratively practicable, but in no event later than March 15 of the year following the year in which Amgen terminates your employment and (2) if you
elect continuation coverage under the Amgen group medical and dental plans for yourself and your qualified beneficiaries under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), Amgen will pay the cost of such coverage
until the earlier to occur of the following: (A) eighteen (18) months following your termination of employment or (B) the date on which you are no longer eligible for such COBRA coverage. Please note that this Termination Paragraph
does not alter the at-will nature of your employment at Amgen. 
 For purposes of the Termination Paragraph, “Cause” means
(i) unfitness for service, inattention to or neglect of duties, or incompetence; (ii) dishonesty; (iii) disregard or violation of the policies or procedures of Amgen; (iv) refusal or failure to follow lawful directions of the
Company; (v) illegal, unethical or immoral conduct; or (vi) breach of the attached Amgen Proprietary Information and Inventions Agreement. 

As an executive at Amgen, you will be eligible for the following: an annual physical examination provided by Amgen; and, reimbursement for up
to $15,000.00, less federal and state tax deductions and other applicable deductions and withholdings, for financial counseling, tax preparation and related services. This value will be treated as imputed income for purposes of tax treatment. 

You will also have the opportunity to participate in our comprehensive benefits program. Amgen’s excellent health care plan currently
includes medical, dental, and vision coverage for you and your eligible dependents. Amgen currently pays the major expense for these programs while staff members share through payroll deductions. Please be advised that in order for you and your
dependents to be eligible for Amgen’s medical coverage you must: 
  

	 	1.	 Report to work at Amgen or another location to which you are required to travel and perform the regular duties of your employment.

  

	 	2.	 Contact the Amgen Benefits Center at 1-800-97AMGEN, to enroll within 31 days of your hire date. 

 

	 	3.	 Meet all other eligibility requirements under the plan. 

The Amgen Retirement and Savings Plan, our 401(k) plan, provides an opportunity for you to save a percentage of your pay (based on Internal
Revenue Service limits) on a tax-deferred basis. Amgen will also contribute to your 401(k) account to help you save for your future financial goals. These benefits, services and programs are summarized in the enclosed brochure called “A Guide
to Total Rewards at Amgen.” 
 This offer of employment is contingent upon confirmation by Amgen of information listed on your
employment application, and the receipt by Amgen of satisfactory results from a background verification and pre-employment drug test (drug test must be taken within 3 business days of receiving written offer). 

Enclosed and included as part of this offer (Attachment 1) is information regarding Amgen’s Proprietary Information and Inventions
Agreement, the Immigration Reform & Control Act, and a packet of materials entitled “Arbitration of Disputes” which includes a Mutual Agreement to Arbitrate Claims. Also enclosed and included as part of this offer in Attachment 1
is information regarding Amgen’s New Staff Member Letter and Certification. This offer is contingent upon you truthfully and accurately completing the Certification, and returning it to the Company before your first day of employment. 

This offer of employment is contingent upon your completing the items described in Attachment 1, and upon your ability to perform for Amgen
all of the duties of your position without restriction from, or violation of, any enforceable contractual obligations owed to any former employer or entity for whom you worked or provided service(s). 

Also enclosed and included, as part of this offer (Offer Letter Benefit Summary), is information about the main points of the relocation
assistance that Amgen will provide to you to relocate to the “local area.” Please note that relocation assistance is contingent upon your execution of the enclosed “Amgen Relocation Agreement for New Hire Staff Members,” subject
to the terms of that Agreement, and that relocation benefits are limited to one benefits package per household. 

  
 2 

 You will be contacted by a Relocation Counselor to initiate your relocation benefits within 7
business days after receipt of your signed acceptance of this offer and your signed New Hire Relocation Agreement. 
 By signing this
letter, you understand and agree that your employment with Amgen is at-will. Therefore, your employment can terminate, with or without cause, and with or without notice, at any time, at your option or Amgen’s option, and Amgen can terminate or
change all other terms and conditions of your employment, with or without cause, and with or without notice, at any time. This at-will relationship will remain in effect throughout your employment with either Amgen Inc. or any of its subsidiaries or
affiliates. This letter, and its enclosures, constitutes the entire agreement, arrangement and understanding between you and Amgen on the nature and terms of your employment with Amgen, including, but not limited to, the kind, character and
existence of your proposed job duties, the length of time your employment will last, and the compensation you will receive. This letter, its enclosures, supersedes any prior or contemporaneous agreement, arrangement or understanding on this subject
matter. By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement, arrangement or understanding, except as referenced in this letter and/or its enclosures. Also, by your execution of this
letter, you affirm that no one has made any written or oral statement that contradicts the provisions of this letter or its enclosures. The at-will nature of your employment, as set forth in this paragraph, can be modified only by a written
agreement signed by both Amgen’s Senior Vice President of Human Resources and you which expressly alters it. This at-will relationship may not be modified by any oral or implied agreement or by any Company policies, practices or patterns of
conduct. 
 The complete terms of the plans, programs and policies referenced to in this letter are set forth in their respective documents,
which are maintained by the Company. The Company reserves the right to amend or terminate any of these plans, programs or policies at any time, in its sole discretion. In the event of any difference between this offer letter and the provisions of
the respective plan, program or policy document, the respective document will govern. 
 You have made an excellent impression on the staff
at Amgen. We are enthusiastic about the contribution you can make, and we believe that Amgen can provide you with attractive opportunities for personal achievement and growth. I look forward to your favorable reply by May 6, 2015. If you
accept our offer, please sign and date the copy of the letter and return it in the enclosed envelope to our Staffing Department along with the completed and signed Proprietary Information and Inventions Agreement and the Mutual
Agreement to Arbitrate Claims. Please retain the original offer letter for your records. If you have any questions regarding this offer, please contact me at (805) 447-XXXX or Greg XXXXXXX at (805) 447-XXXX. 

 

	
	 Sincerely,

	
	 /s/ Stuart A. Tross

	
	 Stuart A. Tross, Ph.D.

	 Senior Vice President, Human Resources

 ST:am 
 Enclosures 

 

			
	 /s/ Jonathan P. Graham
	  	5/19/2015
	 Signature of Acceptance
	  	Date

 XXXX  
 Last 4 Digits of
Social Security Number (For Identification Purposes) 
 Last 4 Digits of Government ID (If No Social Security Number) 

7/13/2015 
 Anticipated Start Date (Hereinafter –
“Hire Date”) 

  
 3 

 ATTACHMENT 1 

In order to accept our offer you will be required to: 
  

	 	A)	 Complete, date and sign the Amgen Proprietary Information and Inventions Agreement and return it with your signed offer letter.

  

	 	B)	 Sign and date the Amgen New Staff Member Letter and Certification and return it with your signed offer letter. 

 

	 	C)	 Date and sign the enclosed Mutual Agreement to Arbitrate Claims and return it with your signed offer letter. 

 

	 	D)	 You will be required to provide Amgen with proof of your identity and eligibility for employment per requirements of the Immigration Reform and
Control Act of 1986 within 3 (three) days of hire. Information pertaining to this Act and required proof are enclosed. 

  

	 	E)	 For California non-exempt staff only, sign and date the Notice To Employee, Labor Code 2810.5 

  
 4 

 NEW STAFF MEMBER LETTER AND CERTIFICATION 

Welcome to Amgen (the “Company”). The Company has no need to learn and does not want any proprietary, confidential or trade secret information or
other property that belongs to any prior employers, entities or other persons you have worked for (collectively, “Prior Employers”). Please review and comply with the following instructions and policies, and execute the Certification
below. 
  

	 	•	 	Carefully read the Company’s Proprietary Information and Inventions Agreement (“PIIA”) that you have executed, and make sure that you understand your obligations under the terms of the PIIA. If you have
any questions, please contact Human Resources. 

  

	 	•	 	You may not bring any material to the Company from third parties in hard copy, in electronic format or in any other form. Nor should you use any such material in your work for the Company. 

 

	 	•	 	Prior to commencing any work for the Company, conduct a search of your personal computer(s), email accounts, and any other electronic storage devices you possess, as well as any files you maintain in hard copy, for
information or materials belonging to your Prior Employers. You are instructed to make appropriate arrangements to return any such information or materials belonging to your Prior Employers, consistent with any obligations you have to the Prior
Employers. 

  

	 	•	 	Do not disclose to or provide the Company with any customer lists you obtained from or during your employment with your Prior Employers. When interacting with doctors or other members of the healthcare industry with
whom you may have had contact while working for your Prior Employers, clearly indicate to such persons that you are an Amgen staff member, and focus on the Company’s products rather than using or discussing information related to your prior
employment. 

  

	 	•	 	If you have any doubts regarding whether you may take, disclose, upload, access, or use any information in your possession, you must err on the side of not taking, disclosing, uploading, accessing or using the
information. 

  

	 	•	 	Do not begin any work for the Company before your employment with your Prior Employers has officially ended. 

  

	 	•	 	After commencing work for the Company, do not request that any employee of your Prior Employers provide you with, or take any other steps to obtain, any information or property of your Prior Employers.

  

	 	•	 	Under no circumstances are you permitted to connect to a Company computer any electronic storage device containing information or property relating to your Prior Employers. Likewise, in performing work for the Company,
you are not permitted to use, disclose, access or upload any such information or property. If you discover that any confidential, proprietary, or trade secret information or property of your Prior Employers has been uploaded to any Company computer
or email system(s), immediately inform Human Resources. 

  

	 	•	 	The Company may monitor and/or conduct an audit of your use of Company computer systems, and you should not have any expectation of privacy in data sent, stored or received on any Company systems. See the Company’s
Use of Company Systems and Internet Conduct Policy for further details. 

  

	 	•	 	Disclose and identify below all agreements relating to your Prior Employers that may affect your eligibility to become employed by and/or to perform work for the Company, including any non-competition agreement(s),
agreements relating to the solicitation of employees or customers, or other restrictive agreements (collectively, “Restrictive Agreements”), regardless of whether you believe these agreements are enforceable, apply to your potential
employment with the Company, or have expired, and provide a copy to Human Resources. If “none,” please so indicate. Do not leave blank. 

  

					
	 Name of Agreement
	 	 Employer
	 	 Date signed

			
	 None
	 	  
	 	 5/19/2015

			
	  
	 	  
	 	  

 (Attach additional sheets, if necessary) 
  

	 	•	 	If you are subject to an agreement not to solicit employees of your Prior Employers, you should refrain from doing so. You should specifically inform Human Resources if you are subject to such an agreement. If you are
subject to such an agreement and a former colleague contacts you about employment opportunities with the Company, please contact Human Resources for assistance. 

  
 5 

	 	•	 	Do not use any email account (including Company email accounts), text messages, Instant Messaging, or any other method of written communication to store or discuss any proprietary, confidential or trade secret
information or other property belonging to your Prior Employers. 

  

	 	•	 	Immediately inform Human Resources if you are contacted in any manner by any former employer regarding your work for Amgen and/or any non-competition agreements, agreements that relate to the solicitation of employees
or customers, or any other restrictive agreements you entered into in connection with any Prior Employers. 

CERTIFICATION 
 I understand that
the above list is only a summary and does not purport to include all of my continuing obligations to the Company. By signing below I certify that I have and will continue to comply with the above instructions and policies. 

I hereby agree that the Company may, at its sole option and discretion contact my Prior Employer(s) to determine whether any Restrictive Agreements exist and,
if so, their applicable terms. I acknowledge that the Company may revoke its offer or terminate my employment if it determines in its reasonable business judgment that I have failed to disclose or am otherwise subject to an enforceable Restrictive
Agreement or my failure to abide by the certifications contained herein. 
 Nothing in this Letter and Certification is intended to alter, or shall have any
impact on, my status as an at-will employee of the Company. In addition to its right to terminate my employment, the Company shall have the right to suspend me from work without pay during its investigation into (1) the existence and/or
enforceability of any restrictions on my ability to perform work for the Company should I fail to disclose a Restrictive Agreement, or (2) the failure to abide by the certifications contained herein. 

I agree: 
  

	
	 /s/ Jonathan P. Graham

	 Signature of Staff Member

  

	
	 Jonathan P. Graham

	 Print Name of Staff Member

 XXXX  
 Last 4 Digits of
Social Security Number (For Identification Purposes) 
 Last 4 Digits of Government ID (If No Social Security Number) 

5/19/2015 
 Date 

  
 6 

 AMGEN SIGN-ON/RETENTION BONUS AGREEMENT 

FOR NEW HIRE STAFF MEMBERS 

I, Jonathan P. Graham, agree to accept my sign-on/retention bonus payment (“Bonus”) from Amgen on the following terms. 

 

	1.	 The amount of the Bonus is described in the offer letter (as may be amended) that was provided separately to me. 

 

	2.	 The Bonus will generally be paid to me as follows: 

  

	 	•	 	 After thirty (30) days following my start date with Amgen, I will be paid $1,000,000.00 as an advance. This amount will be earned only
after I complete two years of employment with Amgen. The Bonus is intended to facilitate my acceptance of employment with Amgen and my continued employment with Amgen for a period of at least two years. Amgen is providing me with the Bonus with the
expectation that I will not resign my employment during this two-year period. 

  

	 	•	 	 $1,000,000.00 to be paid on or about the first anniversary of your start date. I understand that if I am not employed by Amgen on this date,
I have not earned any portion of this amount. 

  

	3.	 I understand and agree that I am an at-will employee and that I am free to resign at any time and Amgen is free to terminate my employment, with or
without cause, at any time. Nevertheless, I understand that if I resign my employment with Amgen before I complete two years of employment, I have not earned any portion of the Bonus amount. Therefore, I agree to repay Amgen for the gross amount of
my Bonus advance if I resign my employment for any reason within 24 months from my hire date at Amgen. I also agree that in the event of such a resignation, the amount to be reimbursed shall be due in full and payable by me immediately in cash
(i.e., by check, wire transfer, or similar immediate payment) without further notice or demand by Amgen. 

  

	4.	 Generally, a sign-on/retention bonus is considered ordinary wage income to the recipient. I understand that Amgen will report to appropriate
federal and state taxing authorities all income that Amgen considers to be subject to taxation and will withhold appropriate taxes in accordance with federal and state regulations. I understand that it is my obligation to declare all income and pay
all taxes owed on such income, if any. 

  

	5.	 I understand that this agreement shall be governed by the law of the State of California. 

 

	6.	 Nothing in this Agreement will be construed as an employment contract or to guarantee me employment at Amgen for any fixed term. I understand that
my employment at Amgen is at will. 

  

	7.	 The provisions of this agreement are severable. If any part is found to be unenforceable, all other provisions shall remain fully valid and
enforceable. 

  

					
	 I agree:
	 		 	 Amgen Inc:

			
	 /s/ Jonathan P. Graham
	 		 	 /s/ Trent Hamilton

	 Signature of Staff Member
	 		 	Signature of Authorized Representative
			
	 Jonathan P. Graham
	 		 	 Director Human Resources

	 Print Name of Staff Member
	 		 	 Title of Representative

			
	 XXXX
	 		 	 5/22/2015

	 Last 4 Digits of Social Security Number (For Identification Purposes)
	 		 	 Date

	 Last 4 Digits of Government ID (If No Social Security Number)
	 		 	

 5/19/2015 
 Date 

  
 7 

 AMGEN RELOCATION AGREEMENT 

FOR NEW HIRE STAFF MEMBERS 

I, Jonathan P. Graham, agree to accept certain relocation benefits from Amgen on the following terms. 

 

	1.	 The relocation benefits to be provided to me are outlined in the Amgen Relocation Policy that applies to staff members at my Global Career
Framework (“GCF”) level. 

  

	2.	 I will obtain relocation benefits from Amgen by following the procedures outlined in the Amgen Relocation Policy that applies to staff members at
my GCF level. 

  

	3.	 I understand that I may obtain an estimate of my relocation costs from Amgen/Amgen’s third-party relocation vendor and that the actual cost of
my relocation may be more or less than the estimate I am provided. I further understand that I can obtain detailed information about the actual services and costs being incurred during my relocation by contacting Amgen or Amgen’s third-party
relocation vendor. 

  

	4.	 The relocation benefits are to facilitate my move as a result of my decision to accept an offer of employment with Amgen. I acknowledge that the
cost of these benefits is not required to be reimbursed to me as a matter of law under California Labor Code section 2802 or any similar statute. 

  

	5.	 Amgen provides the relocation benefits with the expectation that I will not in the short term resign my employment. While, as an at-will employee,
I am free to resign at any time, I agree to reimburse Amgen for the gross amount of the cost of the relocation benefits (according to the schedule below) if I resign my employment for any reason within 730 days of my start date with Amgen. Upon my
resignation, the amount to be reimbursed shall be immediately due and payable by me without further notice or demand. The schedule for reimbursement is as follows: 

 

					
	 Days Since Start Date
	  	% of Gross Cost of Relocation Benefits to be
Reimbursed to Amgen	 
	 0 to 365 days
	  	 	100	% 
	 366- 450 days
	  	 	75	% 
	 451 - 540 days
	  	 	50	% 
	 541 - 730 days
	  	 	25	% 
	 Over 730 days
	  	 	0	% 

  

	6.	 I understand that Amgen will report to federal and state taxing agencies all income that Amgen considers to be subject to taxation. I understand
that it is my obligation to declare all income and pay all taxes owed on such income, if any. 

  

	7.	 In the event that I fail to make a reimbursement required by this agreement and Amgen initiates proceedings to recover such reimbursement, the
prevailing party in such a suit shall be awarded its reasonable costs and attorney’s fees. 

  

	8.	 I understand that this agreement shall be governed by the law of the State of California. 

 

	9.	 Nothing in this agreement will be construed as an employment contract or to guarantee me employment at Amgen for any fixed term. I understand that
my employment at Amgen is at will. Nor does this agreement guarantee me reimbursement of any particular relocation expenses. I understand that reimbursement is governed by the Amgen Relocation Policy and that I must comply with the procedures in
that policy. 

  

	10.	 The provisions of this agreement are severable. If any part is found to be unenforceable, all other provisions shall remain fully valid and
enforceable. 

  

					
	 I agree:
	 		 	 Amgen Inc:

			
	 /s/ Jonathan P. Graham
	 		 	 /s/ Trent Hamilton

	 Signature of Staff Member
	 		 	Signature of Authorized Representative
			
	 Jonathan P. Graham
	 		 	 Director Human Resources

	 Print Name of Staff Member
	 		 	 Title of Representative

			
	 XXXX
	 		 	 5/22/2015

	 Last 4 Digits of Social Security Number (For Identification Purposes)
	 		 	 Date

	 Last 4 Digits of Government ID (If No Social Security Number)
	 		 	

 5/19/2015 
 Date 

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]